News | March 19, 2008

Free Laboratory Test Selection Support Link Available for PDA, via Web

March 20, 2008 - ARUP Laboratories and the University of Utah's Department of Pathology have released ARUP Consult version 2.3, a free laboratory test selection support tool for PDA devices that includes more than 1,500 lab tests categorized into disease-related topics, including clinical background information, test ordering suggestions and concise diagnostic advice.

ARUP Consult is a no-cost Web site that allows physicians to search by disease or condition and find current lab test suggestions, interpretations, algorithms, concise diagnostic advice, and recommendations congruent with national guidelines and supportive links to PubMed and the NGC. It is designed for use at the point of care via the Web or using PDA platforms.

ARUO Laboratories said nearly $5 billion was lost in 2007 because of unnecessary lab testing.

The site offers direct links to national guidelines and relevant references, has more than 40 algorithms to help support clinical decision-making, and has new and updated content released six times a year. The software is co-authored and maintained by ARUP Laboratories' expert panel of University of Utah faculty.

For more information: www.arupconsult.com

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init